Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement

MJBizDaily
By Nick ThomasMay 6, 2019, 6:15 pm196 pts
United Kingdom-based GW Pharmaceuticals showed revenue of $39.2 million for the quarter ended March 31, 2019, compared with $3 million in the same period a year ago. The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Accusations levelled at German medical cannabis importer with Canadian ties 78

From Tariffs to Tech: How U.S. Cone Manufacturing & Automation Are Rewiring Pre-roll Production 77

Vaporizers with CBD, THC now banned in Texas 74

Kid Cudi Cuts Back on Cannabis After Overdoing Blunts 71

High Tide closes acquisition of a majority stake in Remexian Pharma GmbH 70

Last Week in Weed: August 26- September 2, 2025 68

Delaware Officials Tout ‘Strong Rise’ In Marijuana Sales, With $7.3 Million Worth Of Purchases In First Month Of Market Launch 67

Report: Canadian cannabis sector contributes $16 billion to GDP, supports over 227,000 jobs in 2024 55

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.